Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:24:100604.
doi: 10.1016/j.imu.2021.100604. Epub 2021 May 19.

The journey of antimalarial drugs against SARS-CoV-2: Review article

Amany A Sarhan  1 , Nada A Ashour  1 , Ahmed A Al-Karmalawy  1
Affiliations
Review

The journey of antimalarial drugs against SARS-CoV-2: Review article

Amany A Sarhan et al. Inform Med Unlocked. 2021.

Abstract

The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results in vitro and in vivo. This article investigates repurposed antimalarial drugs, focusing on their antiviral mechanisms of action, effects in combinations, trial results, and their side effects.

Keywords: Anti-malarial drugs; COIVD-19; Combination therapy; Drug repurposing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
SARS-CoV-2 lifecycle and several inhibitory mechanisms of CQ/HCQ.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rodrigues‐Diez R.R., et al. Statins: could an old friend help in the fight against COVID‐19? Br J Pharmacol. 2020;177(21):4873–4886. - PMC - PubMed
    1. Bakowski M.A., et al. Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19. BioRxiv. 2020
    1. Ciliberto G., Mancini R., Paggi M.G. Drug repurposing against COVID-19: focus on anticancer agents. J Exp Clin Canc Res. 2020;39:1–9. - PMC - PubMed
    1. Lang J.P., et al. A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020 - PMC - PubMed
    1. Tripathy S., et al. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028. - PMC - PubMed

LinkOut - more resources